Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia

The impact on heterozygous familial hypercholesterolemia (HeFH) health led by high-intensity lipid-lowering therapy (HILLT) is unknown, and the question remains if there is still an unacceptably high residual risk to justify treatment with new lipid-lowering drugs.

Source: Atherosclerosis - February 12, 2019 Category: Cardiology Authors: Sof ía Perez-Calahorra, Martín Laclaustra, Victoria Marco-Benedí, Itziar Lamiquiz-Moneo, Juan Pedro-Botet, Núria Plana, Rosa M. Sanchez-Hernandez, Antonio J. Amor, Fátima Almagro, Francisco Fuentes, Manuel Suarez-Tembra, Fernando Civeira, Dyslipemia Source Type: research